Better Therapeutics, Inc., a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the appointments of Andrew Armanino and Geoffrey Parker to its board of directors.
“As Better Therapeutics embarks on a pivotal trial and prepares for a potential marketing application with the FDA and near-term product launch, it’s essential to have a strong team, and the expertise that Andrew and Geoff bring to our board positions us for success,” said David Perry, co-founder and chairman of Better Therapeutics. “We look forward to their guidance in helping us establish our prescription digital therapeutics as the new standard of care for people with cardiometabolic diseases.”
Mr. Armanino joins the board as the recently retired managing partner and CEO at Armanino LLP, the largest CPA firm based in California. With more than 25 years of experience in various financial and business development leadership roles, Mr. Armanino offers advanced perspectives in business that will help guide the financial decisions of the company. He currently holds board positions at California Bank of Commerce and sits on the AICPA council. He received his bachelor’s degree in accounting from Santa Clara University.
“Joining the Better Therapeutics board is an exciting opportunity to extend my expertise into the digital health space and contribute to the success of this highly innovative company that is tackling serious diseases that are rapidly growing in prevalence, including type 2 diabetes and heart disease,” said Mr. Armanino.
Mr. Parker currently serves as chief operating officer, chief financial officer and executive vice president of Tricida, Inc., and he brings more than 30 years of experience in biotechnology management and healthcare finance. He currently holds board positions for Perrigo Company plc and ChemoCentryx, Inc. Previously, he served as the executive vice president and chief financial officer of Anacor Pharmaceuticals and as a managing director at Goldman, Sachs & Co. Mr. Parker received his A.B. in engineering sciences and economics from Dartmouth College and his MBA from Stanford University.
“Prescription digital therapeutics is a fast-growing sector of the life science industry, and Better Therapeutics has a first-mover advantage and the potential to make its innovative solutions become standard practice for people seeking disease-modifying treatments for behavior-driven indications,” said Mr. Parker.
About Better Therapeutics
Better Therapeutics is a prescription digital therapeutics (PDT) company delivering a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The cognitive behavioral therapy delivered by Better Therapeutics’ PDT enables changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics’ clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines. For more information, visit: bettertx.com.